Glycemic variability and cardiovascular disease in patients with type 2 diabetes
| Autor: | Marcela Martinez, Adrian Pavesi, Guillermo E. Umpierrez, Carla Musso, Jimena Santamarina |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
medicine.medical_specialty Cardiovascular and Metabolic Risk Endocrinology Diabetes and Metabolism Type 2 diabetes Disease Hypoglycemia Diseases of the endocrine glands. Clinical endocrinology chemistry.chemical_compound diagnostic techniques and procedures Diabetes mellitus Internal medicine Medicine Humans In patient Glycemic Glycated Hemoglobin business.industry Blood Glucose Self-Monitoring Gold standard medicine.disease RC648-665 chemistry type 2 Diabetes Mellitus Type 2 Cardiovascular Diseases diabetes mellitus cardiovascular system Glycated hemoglobin business |
| Zdroj: | BMJ Open Diabetes Research & Care BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021) |
| ISSN: | 2052-4897 |
| Popis: | Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose levels. Recent clinical data indicate that GV is associated with increased risk of hypoglycemia, microvascular and macrovascular complications, and mortality in patients with diabetes, independently of glycated hemoglobin level. The use of continuous glucose monitoring devices has markedly improved the assessment of GV in clinical practice and facilitated the assessment of GV as well as hypoglycemia and hyperglycemia events in patients with diabetes. We review current concepts on the definition and assessment of GV and its association with cardiovascular complications in patients with type 2 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|